| US spending on personal health care and public health, 1996-2013 JL Dieleman, R Baral, M Birger, AL Bui, A Bulchis, A Chapin, H Hamavid, ... Jama 316 (24), 2627-2646, 2016 | 1367 | 2016 |
| Contingent valuation of ecotourism in Annapurna conservation area, Nepal: Implications for sustainable park finance and local development N Baral, MJ Stern, R Bhattarai Ecological economics 66 (2-3), 218-227, 2008 | 486 | 2008 |
| Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape NI Mazur, J Terstappen, R Baral, A Bardají, P Beutels, UJ Buchholz, ... The Lancet Infectious Diseases 23 (1), e2-e21, 2023 | 418 | 2023 |
| Global health development assistance remained steady in 2013 but did not align with recipients’ disease burden JL Dieleman, CM Graves, T Templin, E Johnson, R Baral, ... Health Affairs 33 (5), 878-886, 2014 | 170 | 2014 |
| Funding and services needed to achieve universal health coverage: applications of global, regional, and national estimates of utilisation of outpatient visits and inpatient … MW Moses, P Pedroza, R Baral, S Bloom, J Brown, A Chapin, K Compton, ... The Lancet Public Health 4 (1), e49-e73, 2019 | 112 | 2019 |
| Cost of illness for childhood diarrhea in low-and middle-income countries: a systematic review of evidence and modelled estimates R Baral, J Nonvignon, F Debellut, SA Agyemang, A Clark, C Pecenka BMC Public Health 20 (1), 619, 2020 | 86 | 2020 |
| Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study F Debellut, A Clark, C Pecenka, J Tate, R Baral, C Sanderson, U Parashar, ... The Lancet Global Health 7 (12), e1664-e1674, 2019 | 67 | 2019 |
| Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children C Pecenka, E Sparrow, DR Feikin, P Srikantiah, DM Darko, ... The Lancet 404 (10458), 1157-1170, 2024 | 54 | 2024 |
| Potential impact and cost-effectiveness of future ETEC and Shigella vaccines in 79 low-and lower middle-income countries JD Anderson IV, KH Bagamian, F Muhib, R Baral, LA Laytner, M Amaya, ... Vaccine: X 2, 100024, 2019 | 47 | 2019 |
| Costs and cost-effectiveness of malaria reactive case detection using loop-mediated isothermal amplification compared to microscopy in the low transmission setting of Aceh … BW Zelman, R Baral, I Zarlinda, FN Coutrier, KC Sanders, C Cotter, ... Malaria journal 17 (1), 220, 2018 | 40 | 2018 |
| Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model R Baral, D Higgins, K Regan, C Pecenka BMJ open 11 (4), e046563, 2021 | 38 | 2021 |
| Using pre-and post-survey instruments in interventions: determining the random response benchmark and its implications for measuring effectiveness GC Davis, R Baral, T Strayer, EL Serrano Public health nutrition 21 (6), 1043-1047, 2018 | 38 | 2018 |
| Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low-and middle-income country perspective R Wittenauer, C Pecenka, R Baral BMC medicine 21 (1), 121, 2023 | 32 | 2023 |
| The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models R Baral, X Li, L Willem, M Antillon, A Vilajeliu, M Jit, P Beutels, C Pecenka Vaccine 38 (33), 5139-5147, 2020 | 32 | 2020 |
| Financing Global Health 2013: Transition in an Age of Austerity J Dieleman, CJL Murray, A Haakenstad, K Leach-Kemon, R Baral, ... Seattle: Institute for Health Metrics and Evaluation, 2014 | 32 | 2014 |
| Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle … S Mahmud, R Baral, C Sanderson, C Pecenka, M Jit, Y Li, A Clark BMC medicine 21 (1), 138, 2023 | 31 | 2023 |
| Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study F Debellut, A Clark, C Pecenka, J Tate, R Baral, C Sanderson, U Parashar, ... The Lancet Global Health 9 (7), e942-e956, 2021 | 31 | 2021 |
| Malaria elimination transmission and costing in the Asia-Pacific: Developing an investment case R Shretta, SP Silal, OJ Celhay, CEG Mercado, SS Kyaw, A Avancena, ... Wellcome Open Research 4, 60, 2020 | 29 | 2020 |
| Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions RS Laufer, AJ Driscoll, R Baral, AG Buchwald, JD Campbell, F Coulibaly, ... Vaccine 39 (35), 5037-5045, 2021 | 26 | 2021 |
| Costs of continuing RTS, S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries R Baral, A Levin, C Odero, C Pecenka, C Tabu, E Mwendo, G Bonsu, ... PLoS One 16 (1), e0244995, 2021 | 23 | 2021 |
Joseph L DielemanInstitute for Health Metrics and EvaluationVerified email at uw.edu
